NYSE · AMWL
American Well Corporation
$14.98+$0.86 (+6.09%)
American Well Corporation’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
Loading market information…
NASDAQ · EUDA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
EUDA Health Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 78.23% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
EUDA Health Holdings Limited’s next earnings report is currently expected on Mar 3, 2027, with estimated earnings per share of $1.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow EUDA Health Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
EUDA Health Holdings Limited engages in the provision of non-invasive healthcare services primarily in Singapore, Malaysia, and China. It offers bioenergy cabin therapy packages; stem cell therapy services through third-party treatment centers; and holistic wellness consumer products and services. The company also provides property management services. The company was founded in 2019 and is headquartered in Singapore.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | Sep 26, 2024 | -$0.28-1,310.0% vs estimate | $1.05M-53.47% vs estimate |
|---|
| Q2 2024 | Aug 28, 2024 | -$0.020.0% vs estimate | $1.88M+40.3% vs estimate |
|---|
| Q2 2023 | Jul 31, 2023 | -$0.12 | $1.11M |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$14.98+$0.86 (+6.09%)
American Well Corporation’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
$7.44-$0.03 (-0.4%)
Precision BioSciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.66% below the high.
$19.09$0.00 (0.0%)
Fonar Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.34% below the high.
$4.36$0.00 (0.0%)
Adverum Biotechnologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.17% below the high.
$2.17$0.00 (0.0%)
Forian Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.93% below the high.
$0.74-$0.04 (-5.23%)
Hyperfine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.67% below the high.
CA$0.55-CA$0.01 (-1.79%)
Zentek Ltd.’s quoted price sits in the lower half of its reported 52-week range, 63.33% below the high.
$5.37+$0.23 (+4.56%)
aTyr Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.91% below the high.
